Coronavirus (COVID-19)

A letter to our customers from Heather Zenk, SVP, Secure Supply Chain Operations

As we continue to work our way through this challenging time, I simply want to thank you for entrusting me with the privilege of working with you and your dedicated teams as we all get through this together.

Conveyor Belt

Latest updates

AmerisourceBergen and our global pharmaceutical healthcare businesses are monitoring the ongoing spread of the novel COVID-19 coronavirus.

Read the latest updates

We want to hear how AmerisourceBergen is doing to support you during the COVID-19 crisis

Share your feedback via a 2-minute survey.

Take the survey here

The health, safety and well-being of our associates is a top priority during this global pandemic.

We're supporting our front-line associates during COVID-19 with:

  • Enhanced cleaning protocol including EPA-approved disinfectants and additional support from third-party cleaners
  • Back-up dependent care program
  • Enhanced paid time off policy for associates needing to self-quarantine or care for family members

Update on the Distribution of Donated Remdesivir from Gilead Sciences

May 10, 2020

On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19.  Gilead has been working closely with the U.S. government on preparations to donate and distribute remdesivir across the country to treat critical COVID-19 patients, and will work with AmerisourceBergen as the sole distributor for the donated remdesivir.

The U.S. government is coordinating the distribution of remdesivir by determining how much drug each state will receive. Gilead and AmerisourceBergen are working under the guidance of the federal and state governments and state public health departments for the distribution of remdesivir. Neither Gilead nor AmerisourceBergen are deciding which hospitals will receive remdesivir.
For further information, please see HHS’ May 9, 2020 announcement, available at

Retail and specialty pharmacies are not eligible to receive donated remdesivir.

  • For questions about the distribution of remdesivir, call the national remdesivir donation inquiry line at 877-987-4987. 
  • For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit
  • For additional medical information about remdesivir, please visit or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.

We will update this message as additional information becomes available.